Synthesis and evaluation of analogs of the phenylpyridazinone NPD-001 as potent trypanosomal TbrPDEB1 phosphodiesterase inhibitors and in vitro trypanocidals.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Bioorganic & Medicinal Chemistry

• Publication date

  2016-04-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.bmc.2016.02.032PMID 26935942
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Evaluation of pyrrolidine and pyrazolone derivatives as inhibitors of trypanosomal phosphodiesterase B1 (TbrPDEB1).

  2015cited by this paper
• Repurposing human PDE4 inhibitors for neglected tropical diseases: design, synthesis and evaluation of cilomilast analogues as Trypanosoma brucei PDEB1 inhibitors.

  2014cited by this paper
• Synthesis and assessment of catechol diether compounds as inhibitors of trypanosomal phosphodiesterase B1 (TbrPDEB1).

  2013cited by this paper
• Discovery of novel Trypanosoma brucei phosphodiesterase B1 inhibitors by virtual screening against the unliganded TbrPDEB1 crystal structure.

  2013cited by this paper
• Catechol pyrazolinones as trypanocidals: fragment-based design, synthesis, and pharmacological evaluation of nanomolar inhibitors of trypanosomal phosphodiesterase B1.

  2012cited by this paper
• Synthesis and evaluation of human phosphodiesterases (PDE) 5 inhibitor analogs as trypanosomal PDE inhibitors. Part 2. Tadalafil analogs.

  2012cited by this paper
• Pharmacological Validation of Trypanosoma brucei Phosphodiesterases as Novel Drug Targets

  2012cited by this paper
• Synthesis and evaluation of human phosphodiesterases (PDE) 5 inhibitor analogs as trypanosomal PDE inhibitors. Part 1. Sildenafil analogs.

  2012cited by this paper
• Pharmacological validation of Trypanosoma brucei phosphodiesterases B1 and B2 as druggable targets for African sleeping sickness.

  2011cited by this paper
• Target repurposing for neglected diseases.

  2011cited by this paper
• The Human African Trypanosomiasis Control and Surveillance Programme of the World Health Organization 2000–2009: The Way Forward

  2011cited by this paper
• Phosphodiesterase inhibitors as a new generation of antiprotozoan drugs: exploiting the benefit of enzymes that are highly conserved between host and parasite.

  2011cited by this paper
• Therapeutic potential of phosphodiesterase inhibitors in parasitic diseases.

  2011cited by this paper
• The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease.

  2010cited by this paper
• Incidence and nature of infectious disease in patients treated with anti-TNF agents.

  2009cited by this paper
• Empirical Scoring Functions for Advanced Protein-Ligand Docking with PLANTS

  2009cited by this paper
• The Burden of Human African Trypanosomiasis

  2008cited by this paper
• The continuing problem of human African trypanosomiasis (sleeping sickness)

  2008cited by this paper
• The Trypanosoma brucei cAMP phosphodiesterases TbrPDEBl and TbrPDEB2: flagellar enzymes that are essential for parasite virulence

  2007cited by this paper
• Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling.

  2007cited by this paper
• Crystal structure of the Leishmania major phosphodiesterase LmjPDEB1 and insight into the design of the parasite‐selective inhibitors

  2007cited by this paper
• Simple Fibroblast-Based Assay for Screening of New Antimicrobial Drugs against Mycobacterium tuberculosis

  2002cited by this paper
• Novel selective PDE4 inhibitors. 3. In vivo antiinflammatory activity of a new series of N-substituted cis-tetra- and cis-hexahydrophthalazinones.

  2002cited by this paper
• The cAMP-specific phosphodiesterase TbPDE2C is an essential enzyme in bloodstream form Trypanosoma brucei

  2002cited by this paper
• Novel selective PDE4 inhibitors. 1. Synthesis, structure-activity relationships, and molecular modeling of 4-(3,4-dimethoxyphenyl)-2H-phthalazin-1-ones and analogues.

  2001cited by this paper
• Novel selective PDE4 inhibitors. 2. Synthesis and structure-activity relationships of 4-aryl-substituted cis-tetra- and cis-hexahydrophthalazinones.

  2001cited by this paper
• Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors.

  2000cited by this paper
• The Alamar Blue assay to determine drug sensitivity of African trypanosomes (T.b. rhodesiense and T.b. gambiense) in vitro.

  1997cited by this paper
• Suppression of lipopolysaccharide-induced tumor necrosis factor-alpha generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase.

  1995cited by this paper

• Bioengineered 3D microvessels and complementary animal models reveal mechanisms of Trypanosoma congolense sequestration

  2025cites this paper
• Discovery of an Orally Efficacious Pyrazolo[3,4-d]pyrimidine Benzoxaborole as a Potent Inhibitor of Cryptosporidium.

  2024cites this paper
• Structural Investigations of Phthalazinone Derivatives as Allosteric Inhibitors of Human DNA Methyltransferase 3A

  2024cites this paper
• Identification of potent and orally efficacious phosphodiesterase inhibitors in Cryptosporidium parvum-infected immunocompromised male mice

  2024cites this paper
• Adhesion of Crithidia fasciculata promotes a rapid change in developmental fate driven by cAMP signaling

  2024cites this paper
• The Role of Water Networks in Phosphodiesterase Inhibitor Dissociation and Kinetic Selectivity

  2024cites this paper
• Pyridazinone: A privileged scaffold for synthetic and biomedical applications

  2024cites this paper
• Identification of potent and orally efficacious phosphodiesterase inhibitors in sCryptosporidium parvum-infected immunocompromised mice

  2023cites this paper
• Tackling Sleeping Sickness: Current and Promising Therapeutics and Treatment Strategies

  2023cites this paper
• Asymmetric preparation of 2,4, 6‐trisubstituted dihydropyridazinones

  2022cites this paper
• 3-nitroimidazo[1,2-b]pyridazine as a novel scaffold for antiparasitics with sub-nanomolar anti-Giardia lamblia activity

  2022cites this paper
• Discovery of Diaryl Ether Substituted Tetrahydrophthalazinones as TbrPDEB1 Inhibitors Following Structure-Based Virtual Screening

  2021cites this paper
• Homology Modeling and Molecular Dynamics Simulations of Trypanosoma cruzi Phosphodiesterase b1

  2021cites this paper
• From recipe to research: introducing undergraduate students to the nature of science using a hybrid practical course centred on drug discovery for neglected diseases.

  2021cites this paper
• Drug Discovery and Development for Kinetoplastid Diseases

  2021cites this paper
• Cloning and functional complementation of ten Schistosoma mansoni phosphodiesterases expressed in the mammalian host stages

  2020cites this paper
• Lead optimization of phthalazinone phosphodiesterase inhibitors as novel antitrypanosomal compounds.

  2020cites this paper
• Synthetically Important Ring-Opening Acylations of Alkoxybenzenes

  2020cites this paper
• Tetrahydrophthalazinone Inhibitor of Phosphodiesterase with In Vitro Activity against Intracellular Trypanosomatids

  2020cites this paper
• Unpacking the Pathogen Box—An Open Source Tool for Fighting Neglected Tropical Disease

  2019cites this paper
• Análise in vitro da ação combinada de compostos leishmanicidas

  2019cites this paper
• Evaluation of phthalazinone phosphodiesterase inhibitors with improved activity and selectivity against Trypanosoma cruzi.

  2019cites this paper
• Nucleoside analogue activators of cyclic AMP-independent protein kinase A of Trypanosoma

  2019cites this paper
• Flagellar cAMP signaling controls trypanosome progression through host tissues

  2019cites this paper
• Screening of a PDE-focused library identifies imidazoles with in vitro and in vivo antischistosomal activity

  2019cites this paper
• Discovery of novel Schistosoma mansoni PDE4A inhibitors as potential agents against schistosomiasis.

  2019cites this paper
• Alkynamide phthalazinones as a new class of TbrPDEB1 inhibitors (Part 2).

  2019cites this paper
• Alkynamide phthalazinones as a new class of TbrPDEB1 inhibitors.

  2019cites this paper
• Phenyldihydropyrazolones as Novel Lead Compounds Against Trypanosoma cruzi

  2019cites this paper
• Discovery of novel Schistosoma mansoni phosphodiesterase 4A inhibitors as potential agents against schistosomiasis

  2019cites this paper
• Targeting a Subpocket in Trypanosoma brucei Phosphodiesterase B1 (TbrPDEB1) Enables the Structure-Based Discovery of Selective Inhibitors with Trypanocidal Activity

  2018cites this paper
• Cyclic Nucleotide-Specific Phosphodiesterases as Potential Drug Targets for Anti-Leishmania Therapy

  2018cites this paper
• Diverse chemical and biological potentials of various pyridazine and pyridazinone derivatives

  2018cites this paper
• The single cyclic nucleotide-specific phosphodiesterase of the intestinal parasite Giardia lamblia represents a potential drug target

  2017cites this paper
• Vector-borne diseases series Antitrypanosomatid drug discovery: an ongoing challenge and a continuing need

  2017cites this paper
• Phenotypic, chemical and functional characterization of cyclic nucleotide phosphodiesterase 4 (PDE4) as a potential anthelmintic drug target

  2017cites this paper
• Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need

  2017cites this paper
• The therapeutic journey of pyridazinone.

  2016cites this paper